WeightWatchers

Diet Reference Archive: a commercial program

WeightWatchers

A paid program that gives each member a personal budget of Points for food, with an app, group workshops led by the company's own coaches and, in the United States, an optional telehealth service that can prescribe weight-loss medicines. It is sold for weight loss and healthier eating, and its group-meeting versions have been tested in several randomized trials.

Family: Commercial programs and products Promoted by: WW International, Inc., the company that sells the program under the Weight Watchers name First appeared: 1963, the year the company gives for its start GRADE: Moderate for a difference in measured body weight at 12 months, adults with overweight or obesity, group-meeting versions of the program tested from 1998 to 2014 against standard care, brief advice, self-help or free leisure-center visits; this page's own judgment

ON THIS PAGE

1. In brief
2. Overview
3. In practice
4. For the coach
5. The evidence (opens on request)
6. Mechanisms (opens on request)
7. Risks, contraindications and myths (opens on request)
8. Key terms
9. Review questions
10. References
11. Evidence rating and review record

The summary and sections 1 to 3 are the short version and are open when the page loads. Sections 4 to 6 hold the research detail, the biology, and the cautions. Each of those opens when you select its heading, and you can read the page without opening them. Back to the Diet Reference Archive index.

In brief

What is it? A paid membership program run by WW International, Inc. Each member gets a daily and weekly budget of Points, a single number the company calculates for every food from its nutrients, and tracks what they eat in an app. Membership tiers add coach-led group workshops and, in the United States, a telehealth service whose affiliated clinicians can prescribe weight-loss medicines (WW International, Inc., 2026; n.d.-f).

Does it work? In randomized trials of the group-meeting versions, adults offered between 12 weeks and 12 months of the program had lost more weight when they were measured at 12 months than adults given standard care, brief advice or free leisure-center visits, a difference of about 2.3 to 3 kilograms, roughly 5 to 7 pounds (Ahern et al., 2017; Jebb et al., 2011; Jolly et al., 2011). The difference was smaller at 2 years and was not statistically clear at 5 years in the one trial that followed people that long (Ahern et al., 2022).

At 12 months, the trials did not show clear differences in blood pressure or LDL cholesterol (Ahern et al., 2017; Jebb et al., 2011), and the Europe PMC and ClinicalTrials.gov searches for this page did not identify a trial of the program that measured heart attacks, strokes, cancer or deaths. The current app-based version has one 6-month trial, funded by the company, in which diet quality scores and measured weight changed more than with emailed nutrition guidance (Palacios et al., 2025).

Is it safe? The trials recorded harms unevenly: the largest English trial did not formally record adverse events (Ahern et al., 2017), and the 2025 trial reported none (Palacios et al., 2025). In a 12-month trial in adults with type 2 diabetes, more people in the program group than with standard care reported symptoms of low blood sugar at 3 months, 35 against 21 percent, and at 6 months, 29 against 19 percent, and one hospitalization for low blood sugar in the program group was the only serious adverse event the investigators considered possibly related to the study (O'Neil et al., 2016). One trial cannot give a rate of harm for members in general. The company itself bars people under 18, people who are pregnant, and people with an active or recent diagnosis of anorexia nervosa or bulimia nervosa (WW International, Inc., n.d.-c, n.d.-i).

For a coach, 2 cautions matter most. A client taking insulin or a sulfonylurea can have low blood sugar when eating changes (National Institute of Diabetes and Digestive and Kidney Diseases, n.d.), so the client keeps the prescriber informed before a substantial change in eating, and the coach does not change any medicine. A possible low blood sugar episode is treated first under the client's own plan, with emergency help if the symptoms are severe or the person cannot manage the episode, and the prescriber is told afterward. And the program's daily tracking and regular weigh-ins are worth talking through with a clinician for anyone with a history of disordered eating.

Who should not do it without talking to a doctor or dietitian first? Anyone who is pregnant or breastfeeding, and anyone under 18. Anyone with a current or past eating disorder. Anyone taking medicine for diabetes or blood pressure, who keeps the prescriber informed before a substantial change in eating. Anyone with kidney disease, whose needs depend on its stage, laboratory results and whether they are on dialysis, or with another condition treated with a prescribed diet. And anyone considering the company's medication service, where the decision belongs to the prescribing clinician and the client's own physician.

Related pages: Very Low Calorie Diets, Intuitive Eating, Mindful Eating, Noom, Optavia, Meal Replacement Programs, Jenny Craig and Calorie Counting and Tracking Apps. Full list on the archive index.

1. Overview

What you eat

Nothing is assigned. A member eats ordinary food and counts it against a personal budget. The company describes its Points system as a proprietary algorithm that gives each food a value based on its calories, saturated fat, unsaturated fat, added sugar, protein and fiber. A personal assessment sets a daily and weekly Points Budget, and more than 350 foods the company calls ZeroPoint foods do not need to be weighed, measured or tracked (WW International, Inc., 2026). On the company's description, higher sugar and saturated fat push a food's Points up, and protein and fiber bring them down (WW International, Inc., n.d.-g).

In the company-funded trial of the app-based program, the ZeroPoint foods were described as lean proteins, fruits, vegetables, beans, peas, legumes, eggs and nonfat dairy (Palacios et al., 2025). The company also offers versions of the plan adjusted for diabetes, menopause, people taking GLP-1 medicines and people who are breastfeeding (WW International, Inc., 2026; n.d.-b).

What you avoid or limit

No food is forbidden. The company says there are no "good" or "bad" foods, "just nutritious and less nutritious ones," and that "nothing's off limits" (WW International, Inc., n.d.-b, n.d.-f). The limit is the budget: foods higher in sugar and saturated fat cost more Points, so they use up more of the day. This is a guideline built into a number rather than a list of banned foods.

The company's health notice adds its own limits on the pace and the goal. It says the plan is designed for weight loss of up to 2 pounds a week after the first 3 weeks, that members whose body mass index is below 18.5 may not set a weight-loss goal, and that a member may choose to maintain their weight rather than set a weight-loss goal at all (WW International, Inc., n.d.-c).

Where it came from

The company dates the program to 1963 (WW International, Inc., n.d.-a). Its annual report describes the start as weight-loss meetings that its founder, Jean Nidetch, held with friends at her apartment building in the early 1960s, which grew into an organized program built on the idea that people trying to lose weight together succeed more often than people who go it alone (WW International, Inc., 2026). Federal securities filings list the company as Weight Watchers International until 2019 and as WW International, Inc. since then (U.S. Securities and Exchange Commission, n.d.); its pages use both "Weight Watchers" and "WeightWatchers" for the brand, and many research papers call it WW.

The program has changed many times, which matters when reading its research. A 2006 British trial tested what it called the Weight Watchers "Pure Points Programme," an energy-controlled diet with weekly group meetings (Truby et al., 2006). A 2017 trial tested Weight Watchers Online, a web-only version (Thomas et al., 2017). The 2025 trial tested the app-based program with Points, ZeroPoint foods and virtual workshops (Palacios et al., 2025). The company now also runs a medical service: its U.S. Med+ tier gives members access to affiliated clinicians who can prescribe weight-loss medicines, including GLP-1 medicines in pill and injection form (WW International, Inc., 2026).

Company and business status changes, so it was checked for this page. The company and some of its subsidiaries filed for Chapter 11 bankruptcy on May 6, 2025, and emerged from it on June 24, 2025, with about $1.1 billion in loans and $500 million in notes discharged under the reorganization plan. The company's annual report for 2025 lists its recent emergence from bankruptcy first among its risks, and the company was still filing reports as a public company in 2026 (U.S. Securities and Exchange Commission, n.d.; WW International, Inc., 2026).

What it claims to do

The company describes its purpose as helping people "not just to lose weight, but to keep it off and live healthier lives" (WW International, Inc., n.d.-a). Its pages call it "the #1 doctor-recommended weight-loss program," a claim footnoted to a 2023 survey of 500 doctors who recommend weight-loss programs to patients, and "the only weight-loss brand backed by 60 years of proven science" (WW International, Inc., n.d.-f). Its website cites "more than 175 publications" showing the program's efficacy, and its annual report cites over 180 peer-reviewed publications, 65 of them with randomized trial data (WW International, Inc., 2026; n.d.-f).

For the medical tier, the company states that "our Med+ members lose 21% of their body weight in 12 months on average with a GLP-1 medication," footnoted to its own data on about 3,250 clinic patients (WW International, Inc., n.d.-d). A similar 21 percent figure on the company's About page is footnoted as an internal analysis of members' self-reported weights, with the note that these are "not randomized, controlled clinical trials" and that "self-reported outcomes have not been independently verified" (WW International, Inc., n.d.-a). For the app program, the company says it is "proven to improve your diet quality," citing the 2025 trial it funded (WW International, Inc., n.d.-f). Section 4 reports what the research found behind these claims.

What it gets right

Several of the program's features line up with mainstream guidance. Among the features of a heart-healthy dietary pattern, the American Heart Association lists eating plenty of vegetables and fruits, choosing healthy sources of protein, choosing unsaturated fats in place of saturated fat, and minimizing added sugars (Lichtenstein et al., 2026). A Points system that makes saturated fat and added sugar cost more, and that leaves many vegetables, fruits, beans and lean proteins untracked, pushes daily choices in that direction, on the company's own description of how Points are calculated (WW International, Inc., 2026; n.d.-g).

Some of its framing is also careful. The company does not ban foods, lets members choose a goal other than weight loss, bars members with a body mass index below 18.5 from setting a weight-loss goal, asks members to show the plan to their health care provider if they are being treated for a condition, and states that it is not a medical organization (WW International, Inc., n.d.-c). And the group-meeting program has been tested against standard care in randomized trials run in several countries, some of them funded independently of the company (Ahern et al., 2022; Jolly et al., 2011). These are the parts a coach can honor in a client's reasons without endorsing the whole package.

How clients describe it, and what it gets confused with

Clients say "I'm doing Weight Watchers," "I'm on WW," "I have 6 Points left," "that's a zero-point food," "my weigh-in day," "my workshop" or "my coach." Clients on the medical tier may say "I'm on Med+" or "I get my GLP-1 through Weight Watchers." The company's own pages answer people who have "tried Weight Watchers before" (WW International, Inc., n.d.-f), and the version a returning client remembers may be much older than the one now sold. Food products sold under the brand are made under trademark licenses and are not the program itself (WW International, Inc., 2026).

It can be confused with other paid programs. Noom is another app-based program. A 2015 review classed WeightWatchers as a program of low-calorie conventional foods with Points tracking and classed Jenny Craig as a program built on low-calorie meal replacements (Gudzune et al., 2015); shakes and bars sold as meal replacements, as in Optavia, are a different approach, listed on the archive index under Meal Replacement Programs. Very Low Calorie Diets are medically supervised total diet replacement, a different treatment. And a client who tracks food in a free app is doing something close to the program's core habit without the program; Calorie Counting and Tracking Apps is listed as a separate topic on the archive index.

2. In practice

A typical day of eating

The day described here is this page's own illustration, built from the company's description of how Points work. Breakfast might be eggs scrambled with spinach and peppers, a slice of whole-grain toast and coffee with milk; on the company's description, the eggs and vegetables are ZeroPoint foods and the toast and milk use Points. Lunch is a salad with chicken, beans and an oil-and-vinegar dressing, with the dressing counted. An apple and a nonfat yogurt fill the afternoon. Dinner is salmon, brown rice and roasted broccoli at home, or a restaurant meal looked up in the app. Through the day the member logs each item by photo, barcode or search, watches the budget fall, and checks in on a set weigh-in day (WW International, Inc., 2026; n.d.-g).

What takes effort is not unusual food but counting. Any food is allowed if it fits the budget, so a member who spends most of the day's Points on dessert is following the rules as written, and the quality of the day depends on the choices the member makes within it.

Cost, products, and who profits

The program is sold by subscription in 3 tiers. Core is the app; Core+ adds unlimited coach-led workshops, in person or online; and Med+, in the United States only, adds access to clinicians who can prescribe weight-loss medicines (WW International, Inc., 2026). On the company's pages checked on October 11, 2026, Core was advertised at $10 a month for the first 12 months of a 12-month plan, and Core+ at $20 a month, in offers ending October 15, 2026; after the offer period the plan renews at the regular price, which was not displayed because the plan comparison on the page did not load (WW International, Inc., n.d.-f).

Med+ was advertised at $25 for the first month, then $74 a month on a 12-month plan or $84 a month on a 6-month plan, with the cost of GLP-1 medicines not included (WW International, Inc., n.d.-d). Visits with a registered dietitian cost $99 each without insurance, or as little as $0 with qualifying insurance (WW International, Inc., n.d.-e). Plans renew automatically, and fees for a period that has started are generally not refundable (WW International, Inc., n.d.-i). For comparison, a 2015 review listed the program at about $43 a month in December 2014 (Gudzune et al., 2015).

The company is the main party that profits, through subscriptions: it reported about 2.6 million subscribers to its app and workshop tiers and about 130,200 to its medical tier at the end of 2025. It also earns money by licensing its trademarks for food and other products, from franchise fees and royalties, from publishing, and through contracts with employers and health plans (WW International, Inc., 2026). The medical tier also involves affiliated medical groups and the pharmacies that dispense the medicines (WW International, Inc., n.d.-h). Many of the trials described on this page were funded by the company or had company employees among their authors, which section 4 notes trial by trial.

For a person with limited money, the food itself is ordinary groceries, and nothing in the plan requires special products. The cost is the membership, the smartphone the app needs, and, for the medical tier, the medicine. Some public programs have paid for memberships: in England, primary care practices referred patients to the program in trials (Ahern et al., 2017; Jolly et al., 2011), and Tennessee's Medicaid program offered it to its members for a nominal fee in 2006 (Mitchell et al., 2013).

Environmental footprint

Neff and colleagues (2023) modeled the greenhouse gas emissions and water use of 7 commercial diet patterns from company guidance and sample menus. The WeightWatchers pattern had estimated emissions below those of the average U.S. diet, as did the ketogenic, DASH and MyPlate patterns, but still 2.4 to 3.0 times the target the EAT-Lancet commission set for sustainable food production; the authors attribute part of that result to the low calorie intake of these plans. These are modeled cradle-to-farmgate estimates for the guidance the company published at the time, not measurements of what members eat. Within the plan, a member's footprint depends mostly on the foods chosen, especially how much beef and dairy (Neff et al., 2023).

Cultural fit

Because no food is banned, the plan can be followed with the foods of almost any tradition, as long as the member can find or estimate their Points; the company lists more than 12,000 recipes and more than 600 restaurant guides in its app (WW International, Inc., n.d.-g). The research base is narrower than the membership. The participants in the main trials were mostly women, and in the largest British trial 90 percent were White (Ahern et al., 2017); in the 2025 U.S. trial about two-thirds identified as non-Hispanic White, and about 18 percent reported food insecurity (Palacios et al., 2025).

What follows is observation rather than a research finding. A program built on counting and weighing sits easily with some families and uneasily with others, for example where meals are shared from common dishes and portions are not measured, or where weight talk at home is unwelcome. A coach can ask how counting would work at the client's own table.

What makes people stop

Many people stop early. In the 4-diet trial in Boston, 26 of the 40 people assigned to WeightWatchers completed the year (Dansinger et al., 2005). In the 3-country referral trial, 61 percent of those referred to the program completed the 12-month assessment (Jebb et al., 2011). In Tennessee's Medicaid program, more than 13 percent of participants attended only 2 meetings, and people who attended more meetings lost more weight, an association that cannot separate the meetings from the kind of person who keeps coming (Mitchell et al., 2013). The company itself lists keeping and growing its subscriber base among its main business risks (WW International, Inc., 2026).

Beyond those figures, what follows is observation: the reasons people are likely to leave include the cost of a monthly subscription, the work of logging every meal, weigh-ins that feel discouraging, and changes in life that make the routine hard to keep.

What happens when you stop

The longest trial shows what happens over time. In the English trial, all 3 groups regained some weight between 12 and 24 months, and the differences between the groups became smaller (Ahern et al., 2017). At 5 years, average weight loss from the start was 0.46 kilograms in the brief-advice group, 1.95 kilograms in the 12-week program group and 2.67 kilograms in the 52-week program group, and the differences between groups were not statistically clear (Ahern et al., 2022). In a U.S. trial that followed people for 2 years, the program group lost an average of 4.3 kilograms against 1.3 kilograms with self-help at 1 year, and 2.9 against 0.2 kilograms at 2 years (Heshka et al., 2003).

Some members do keep weight off. A company-funded survey of 4,786 members who had kept off at least 9.1 kilograms, an average of 3.3 years, found that they reported more frequent healthy eating, self-monitoring and coping strategies than a comparison group of people with obesity whose weight had been stable (Phelan et al., 2020). Members who answered that survey were selected because they had succeeded, so it describes what successful maintainers do, not how many members succeed.

Common variations

Within the company, a client may be on Core, the app alone; Core+, the app with workshops; or Med+, which adds prescribing clinicians and medicines (WW International, Inc., 2026). Core+ and Med+ include programs tailored for diabetes, menopause and people taking GLP-1 medicines, and the company offers adjustments for breastfeeding (WW International, Inc., n.d.-b). Older versions a client may remember include the Pure Points version tested in a 2006 British trial and the web-only Weight Watchers Online tested in a 2017 U.S. trial (Thomas et al., 2017; Truby et al., 2006).

The company also once marketed a coaching app for children and teenagers. An archived copy of its website from December 2020 shows it as "Kurbo by WW (Weight Watchers)," a program for kids and teens built on a traffic light system of green, yellow and red foods (WW International, Inc., 2020). The kurbo.com address did not open when tried for this page, and the company's current health notice bars anyone under 18 from its plan (WW International, Inc., n.d.-c).

In 2022, a federal case over the Kurbo app ended in a settlement. The Federal Trade Commission alleged that WW International and its subsidiary Kurbo, Inc. marketed the app for children as young as 8 and collected their personal information without their parents' permission, in violation of the federal rule on children's online privacy. The court-approved order required the companies to delete personal information collected from children under 13 without proper parental notice and consent, destroy any algorithms derived from that data, and pay a $1.5 million civil penalty (Federal Trade Commission, 2022). This was a privacy and commercial practice case. It is not evidence about whether the app's eating guidance helped or harmed children.

3. For the coach

SCOPE OF PRACTICE

A health and wellness coach does not prescribe, adjust, endorse, or discourage WeightWatchers or any other way of eating, and does not diagnose or treat. The coach helps the client understand what they have chosen, notice how it is going, and decide what to do next. Two points belong to someone else. Any decision about a weight-loss medicine, including one prescribed through the company's Med+ service, belongs to the prescribing clinician and the client's own physician. And a client with a diagnosed condition that eating affects, such as kidney disease, needs the clinician and registered dietitian who manage it, because needs depend on the stage of the condition, laboratory results and treatment, including, for kidney disease, whether the person is on dialysis.

The company calls its workshop leaders Coaches and describes them as trained in its nutrition and behavior change science (WW International, Inc., n.d.-g). That is a company role. It is a different thing from a health and wellness coach working under a professional scope of practice. The company pages opened for this page describe training in the company's own approach and do not list a professional health credential as a requirement for the role; that does not mean that no individual Coach holds one. A client may have both, and the two can work side by side.

The program's risks fall on particular groups rather than on adults in general. For a client in any of these 5 groups, the coach's role includes making sure the client has medical oversight for the change:

• A current or past eating disorder or disordered eating: the company itself bars people with an active or recent diagnosis of anorexia nervosa or bulimia nervosa, so the client's clinician is involved first, through the coach’s own referral process or an existing care plan.
• Pregnant: the company does not allow enrollment during pregnancy, so the obstetric clinician decides; breastfeeding: the obstetric or pediatric clinician and a registered dietitian.
• Under 18: the company's plan is closed to anyone under 18, and a young person's eating belongs to the family and the pediatric clinician.
• Taking insulin, a sulfonylurea or blood pressure medicine: the client keeps the prescriber informed before a substantial change in eating.
• Taking or considering a weight-loss medicine through Med+ or elsewhere: questions about the medicine, its dose and its side effects go to the prescriber.

Who does what

The physician

Decides whether a weight-loss plan is medically appropriate for this person, especially with diabetes, heart or kidney disease, gallbladder disease or a history of an eating disorder, and adjusts diabetes and blood pressure medicines as eating and weight change. The company's own health notice urges members to consult their primary health care provider before starting and to have periodic checkups, noting that weight loss can aggravate gallbladder illness (WW International, Inc., n.d.-c). For a member on the medical tier, the prescribing clinician manages the weight-loss medicine, and the client's own physician needs to know about it.

The registered dietitian

Builds an eating plan for a diagnosed condition, such as diabetes or kidney disease, and checks whether the foods a member chooses within the Points budget meet their nutrient needs, particularly calcium, iron and other nutrients whose intake fell in one trial of an earlier version of the program (Truby et al., 2008). A dietitian can also help a member taking a medicine that reduces appetite plan meals that still meet their needs. The company now offers visits with registered dietitians as an add-on (WW International, Inc., n.d.-e); a client's own dietitian may already know their history.

The health and wellness coach

Helps the client get clear about what they want from the program and why now, and test it against the life they live: the budget for a monthly subscription, the time it takes to log meals, how weigh-ins feel, and who else eats at their table. With the client's permission, can share general information about what the research does and does not show. Notices whether tracking is serving the client or starting to run them, keeps the conversation about the client's own goals rather than a number on the scale, and holds the referral line. The coach's part is the client's reasons, plans and follow-through over time.

What a client bringing this diet needs

Clients bring WeightWatchers for familiar reasons: a doctor said to lose weight, a friend or coworker had success, they did it years ago and it worked for a while, or they want structure and company rather than doing it alone. Some clients now come because they want a GLP-1 medicine and the company offers a way to get one. The reason shapes the conversation. A client who wants a weekly group for accountability needs something different from a client who has rejoined 5 times and feels like a failure, and different again from a client about to start an injection.

What a coaching conversation offers that the app cannot is room to separate the client's goal from the program's numbers. A coach avoids moral language about food and any framing that treats eating less or weighing less as the aim. The program's own vocabulary of budgets, points and weigh-ins is worth noticing in the same way: the coach listens for how the client talks about a day over budget, rather than adopting the program's numbers as the measure of the client's success.

What to ask

• "What are you hoping will be different 6 months from now, apart from the scale?"
• "When you have used the program before, what helped, and what got in the way?"
• "How do you feel on a day when you go over your Points, and what do you do next?"
• "Who on your health care team knows you are starting this, and what did they say about your medicines?"

Referral red flags

A client taking insulin, a sulfonylurea or a meglitinide who is about to cut back what they eat keeps the prescriber informed before the change, because eating fewer carbohydrates or skipping or delaying meals can make blood glucose drop too low on these medicines (National Institute of Diabetes and Digestive and Kidney Diseases, n.d.). A client who reports shakiness, sweating or confusion may be having a low blood sugar episode right now; the first step is the one in their own diabetes plan for treating it, with emergency help if the symptoms are severe or the person cannot manage the episode under their plan, and telling the prescriber is the separate step that follows.

The company lists nausea, constipation and other gastrointestinal discomfort as the most common side effects of GLP-1 medicines (WW International, Inc., n.d.-d). A client on a weight-loss medicine who describes vomiting that does not stop, cannot keep fluids down, or has severe abdominal pain is describing something for the prescriber to assess promptly; the coach does not guess at the cause. The company's own health notice says its plan is designed for weight loss of up to 2 pounds a week after the first 3 weeks and asks members who lose faster to adapt the plan (WW International, Inc., n.d.-c). Weight a client is losing without meaning to is a reason to involve a clinician, never a sign the program worked.

Some patterns call for a closer look at the eating itself: skipping meals to save Points, eating very little before a weigh-in, distress or self-criticism after a day over budget, avoiding meals with others because they cannot be tracked, or rejoining again and again with growing distress. On their own, such behaviors tell a coach little, and many have ordinary reasons, from a work schedule to a household's routines. The coach asks what the behavior is for, whether it causes distress, whether it is narrowing what the person eats, and whether it is getting in the way of daily life. Where the answers raise a real concern about disordered eating, the coach follows their own referral process, or brings the concern to the client's clinician under an existing care plan.

Special populations

Pregnancy and breastfeeding

The company states that a person may not enroll while pregnant, because its services "are not designed, or tailored for pregnant members," and recommends that a member who becomes pregnant cancel until a health care provider advises resuming, or discuss with the provider whether continuing is suitable (WW International, Inc., n.d.-i). The main trials excluded pregnancy (Ahern et al., 2017; Palacios et al., 2025). The company offers adjustments to the plan for breastfeeding (WW International, Inc., n.d.-b); the searches for this page did not identify a trial testing the program during breastfeeding. One British audit followed 82 women of childbearing age, referred to a 12-week program while considering or planning a pregnancy; 34 completed it (Tocque & Kennedy, 2022). Any plan to change eating during pregnancy or breastfeeding belongs with the obstetric clinician and a registered dietitian.

Children and adolescents

The company's health notice prohibits participation in its plan by anyone under 18 (WW International, Inc., n.d.-c). It previously marketed Kurbo, a coaching app for children and teenagers (WW International, Inc., 2020); the 2022 federal privacy settlement over Kurbo, described in section 2, concerned the collection of children's data, not the app's effects on their health (Federal Trade Commission, 2022). The studies of Kurbo found for this page are retrospective analyses of user data, without a comparison group, in which children who received more coaching sessions had larger decreases in weight status (Cueto et al., 2019; Jelalian et al., 2023); the authors of the second called for studies with a comparison condition and verified measurements. The searches for this page did not identify a randomized trial of the program in children. A coach works with the adult in front of them; a child's eating belongs to the family and the pediatric clinician.

Older adults

The searches for this page did not identify a trial designed for older adults. The main trials enrolled adults up to their 60s and 70s; the largest English trial had a mean age of 53 (Ahern et al., 2017), and the Boston trial enrolled people aged 22 to 72 (Dansinger et al., 2005). An older client who wants to join, especially one taking several medicines or with a small appetite, is a client for the physician and a registered dietitian first.

Athletes and people with high activity

The searches for this page did not identify a study of the program in athletes. The Points budget is set by the company's assessment, and whether it meets the energy needs of heavy training has not been tested in the studies found; that question belongs to a sports dietitian.

People taking medication for diabetes, blood pressure, or blood thinning

Insulin and some other diabetes medicines can cause low blood glucose when a person eats too little carbohydrate or skips or delays meals (National Institute of Diabetes and Digestive and Kidney Diseases, n.d.). In a 16-center U.S. trial in adults with type 2 diabetes, 26 percent of the program group reduced their diabetes medicines, against 12 percent with standard care, and more of the program group reported symptoms of low blood sugar in the first 6 months. The participants' own physicians, outside the study, managed their diabetes medicines; the study's diabetes educators, who were also registered dietitians, advised on adapting the program and on preventing and treating low blood sugar (O'Neil et al., 2016). For warfarin, the federal MedlinePlus guidance asks people to eat consistent amounts of vitamin K-containing food from week to week and to talk to their doctor before changing their diet (National Library of Medicine, 2026), which matters if a client starts eating far more leafy greens. For any of these medicines, the standing rule is that the client keeps the prescriber informed before a substantial change in eating, rather than asking permission for every food choice. The company itself asks members on prescription medicines to show the plan to their health care provider (WW International, Inc., n.d.-c).

People with a history of disordered eating

The company bars this group in 2 differently worded statements: its health notice prohibits participation by anyone "diagnosed with or treated for anorexia nervosa or bulimia nervosa in the last year," and its membership agreement says the services are for people who "do not have an active eating disorder diagnosis" (WW International, Inc., n.d.-c, n.d.-i). The trials' exclusions differed: the English WRAP trial excluded people with eating disorders, the 3-country trial excluded anyone with a history of a clinically diagnosed eating disorder, and the online trial excluded any lifetime eating disorder diagnosis except binge eating disorder (Ahern et al., 2017; Jebb et al., 2011; Thomas et al., 2017). The main reports of the diabetes trial and the 2025 trial do not list eating disorders among their exclusions, and their full eligibility lists, in supplements, were not read for this page (O'Neil et al., 2016; Palacios et al., 2025). The searches for this page did not identify a study measuring the onset or return of disordered eating in members. The program asks for daily tracking, a numerical budget and regular weigh-ins, and for someone with this history those features are worth discussing with their clinician before joining. A client with this history is referred to their clinician, or through the coach’s own referral process if they have none.

Client misconceptions

Three come up most. The first is that the program keeps weight off for good. In the longest trial, the difference between the program and brief advice shrank between 1 and 2 years and was not statistically clear at 5 years (Ahern et al., 2017; Ahern et al., 2022). The second is that "#1 doctor-recommended" means doctors have found it works better than other programs. That phrase comes from a survey of doctors' recommendations, and in the trials that compared it directly with other popular diets, no clear difference between the diets was found (Dansinger et al., 2005; Truby et al., 2006). The third is that the large weight changes advertised for Med+ come from the program's habits; they come from members taking prescription medicines, as reported in the company's own unverified data (WW International, Inc., n.d.-a). Each is taken up in section 6.

🤝 COACHING CONNECTION

Denise tells her coach she has rejoined WeightWatchers 4 times and is thinking about upgrading to get a GLP-1 prescription through the app. She says she always does well for a few months and then "falls off." The coach reflects that she sounds both hopeful and tired of starting over, and asks what was happening in her life each time she stopped. Denise says it was usually a busy stretch at work, when logging every meal felt impossible. The coach asks what she would want to keep from the program if logging fell away, and whether her own doctor knows she is considering a medicine. Denise decides to ask her doctor about the medicine first, and to try the workshops she has never attended, because she misses having people to check in with. Nothing was recommended, and the program was never evaluated.

4. The evidence

(select the heading to open or close this section)

WeightWatchers has a trial base of its own. Randomized trials of the group-meeting versions, run in the United States, England, Australia and Germany, show more weight change at 12 months than standard care, brief advice or self-help, by about 2.3 to 3 kilograms on average, with the difference shrinking over the following years. At 12 months they did not show clear differences in blood pressure or LDL cholesterol, and none of the trials found for this page measured heart attacks, strokes, cancer or deaths. Each study below says which version of the program it tested, because the program has changed many times. The certainty ratings are in the Evidence rating and review record at the end of the page.

Which version each trial tested

The trials span about 25 years and several different programs under one name. The U.S. self-help trial, run from 1998 to 2001, tested a commercial program of a food plan, an activity plan and a behavior modification plan delivered at weekly meetings, which a 2015 review classed as a WeightWatchers trial (Gudzune et al., 2015; Heshka et al., 2003). The British diet trial tested the Pure Points version with weekly group meetings (Truby et al., 2006). The 3-country referral trial gave 12 months of free access to weekly community meetings, with internet tools available (Jebb et al., 2011), and the English trials gave 12 or 52 weeks of free meetings by referral from a family doctor (Ahern et al., 2017; Jolly et al., 2011).

Two U.S. trials tested versions adapted for a medical purpose: a modified program for people with prediabetes, and the standard program plus telephone and email support from a certified diabetes educator for people with type 2 diabetes (Marrero et al., 2016; O'Neil et al., 2016). One trial tested Weight Watchers Online, a web-only version (Thomas et al., 2017). The most recent trial tested the app-based program sold in 2023, with Points, ZeroPoint foods and virtual coach-led workshops (Palacios et al., 2025). No trial found for this page tested the program in its current form for longer than 6 months, and none tested the Med+ medical tier against usual care.

Evidence from randomized controlled trials

A trial assigns people to the program by chance and compares them with people assigned to something else, which is the strongest way to test whether the program itself causes a result. The trials of WeightWatchers share 3 limitations. Participants knew which group they were in; in some trials the staff who weighed people or the laboratory that tested blood did not know, and in others they did. Many participants were not measured at the end, often a third or more, so the results depend on assumptions about the missing people. And the company funded several of them or employed some of their authors; the trial descriptions below say which.

Cardiometabolic outcomes

A 2016 systematic review of commercial programs found that, at 12 months, WeightWatchers showed "little change in blood pressure or lipid outcomes" compared with control or education, from 2 trials, in participants whose blood pressure and lipids were mostly normal at the start; it judged the risk of bias high for most trials (Mehta et al., 2016). In the 3-country referral trial, insulin and the ratio of total to HDL cholesterol improved more with the program than with standard care, while the small falls in blood pressure did not differ between groups (Jebb et al., 2011). In the English trial, blood pressure and cholesterol changed little and did not differ clearly between groups at 12 months (Ahern et al., 2017).

Read against the smallest differences a 2020 review of named diets treated as important, 3 mm Hg for systolic blood pressure and 5 mg/dL, about 0.13 mmol/L, for LDL cholesterol (Ge et al., 2020), the combined blood pressure results point to little or no important difference; the LDL conclusion remains uncertain because it depends on how missing measurements are handled. In the English trial, systolic pressure at 12 months was 1.04 mm Hg lower with the 52-week program than with brief advice, from 3.64 lower to 1.56 higher, and LDL cholesterol differed by 0.00 mmol/L, from 0.19 lower to 0.19 higher, with blood results from 830 of 1,267 people. In the 3-country trial, systolic pressure was 0.71 mm Hg lower with the program, from 2.35 lower to 0.92 higher, and LDL cholesterol 0.05 mmol/L lower, from 0.13 lower to 0.03 higher (Ahern et al., 2017; Jebb et al., 2011).

Blood sugar results come mainly from people with or near diabetes. In the English trial's optional blood tests, HbA1c, a measure of average blood sugar, fell more in the 52-week program group than with brief advice, by 2.65 mmol/mol, from 1.01 to 4.28, at 12 months; the 12-week program did not differ from brief advice (Ahern et al., 2017). In a 12-month trial of 225 adults with prediabetes in Indianapolis, people in a modified version of the program improved HbA1c more than people given a self-initiated program using materials from the National Diabetes Education Program; 2 of the authors were company employees (Marrero et al., 2016).

In a 12-month trial at 16 U.S. centers, 563 adults with type 2 diabetes were randomized: 279 to the standard program, with community meetings and online tools, plus telephone and email support from a certified diabetes educator, and 284 to one session of diabetes nutrition counseling with a registered dietitian and written materials afterward. The educators were also registered dietitians. The participants' own physicians, outside the study, managed their diabetes and its medicines and received the study's laboratory results. At 12 months, 230 of the program group and 254 of the standard care group attended, and HbA1c results were available for 223 and 250. Blood was analyzed at a central laboratory blind to group, and the university coordinating center analyzed the data independently of the company, which funded the trial and employed 3 of its authors at the time (O'Neil et al., 2016).

HbA1c fell by 0.32 percentage points with the program and rose by 0.16 with standard care, a difference of about 0.48 points; analyses that handled missing data in 2 other ways gave nearly identical results. The trial was planned around a difference of 0.3 points. At 12 months, 24 percent against 14 percent had an HbA1c below 7.0 percent, and 26 percent against 12 percent had reduced their diabetes medicines. More of the program group reported symptoms of low blood sugar at 3 months, 35 against 21 percent, and at 6 months, 29 against 19 percent, with no clear difference at 9 or 12 months. One hospitalization for low blood sugar, in the program group, was the only serious adverse event the investigators considered possibly related to the study (O'Neil et al., 2016).

A later company-funded study of a virtual diabetes version had no comparison group, so its HbA1c fall of 0.75 percentage points over 24 weeks cannot be attributed to the program (Apolzan et al., 2023).

Cancer

The searches for this page did not identify a trial of the program that measured cancer incidence or cancer outcomes, and the studies reviewed here do not establish any effect of the program on cancer.

Body weight, as measured

This archive reports body weight as something a study measured, in that study's own numbers, and not as a goal or as a measure of whether a program worked; see the standing rule in the review record at the foot of this page. The one exception is weight a person loses without meaning to, which can signal a health problem and is a reason to involve a clinician, never a sign that a program worked.

In the 3-country trial, 772 adults with overweight or obesity and at least one weight-related risk factor were recruited by primary care practices in Australia, Germany and the United Kingdom and assigned to 12 months of standard care or 12 months of free meetings. At 12 months, 230 of 377 in the program group and 214 of 395 in the standard care group completed the assessment. Counting each missing person's last recorded weight, the program group lost 5.06 kilograms and the standard care group 2.25, an adjusted difference of 2.77 kilograms, from 2.03 to 3.50; counting each missing person as unchanged, the difference was 2.29 kilograms. The company funded the trial through a grant to the U.K. Medical Research Council and delivered the program, and the report says it had no role in the design, analysis or writing (Jebb et al., 2011).

The English WRAP trial assigned 1,267 adults from 23 primary care practices to brief advice and self-help materials, 12 weeks of the program or 52 weeks of the program, in a 2 to 5 to 5 ratio. At 12 months, 65 percent were measured. Average weight change was 3.26 kilograms lost with brief advice, 4.75 with 12 weeks and 6.76 with 52 weeks; the program groups together lost 2.71 kilograms more than brief advice, from 1.55 to 3.86, and 52 weeks lost 2.14 kilograms more than 12 weeks. At 2 years, all groups had regained some weight, and the program groups together had lost 1.44 kilograms more than brief advice, with a confidence interval reaching no difference. The trial was funded by a national research initiative and by the company through a U.K. Medical Research Council industrial collaboration award (Ahern et al., 2017).

At 5 years, weight was available for 871 of the 1,267, 69 percent. The 52-week program group had lost 1.76 kilograms more than the brief-advice group, from 3.68 kilograms more to 0.17 kilograms less, and the 12-week group 0.96 kilograms more, from 2.90 more to 0.97 less; neither difference was statistically clear. This 5-year report, funded by the U.K. National Institute for Health and Care Research and the Medical Research Council, was read as its abstract, because the full text refused the fetch (Ahern et al., 2022).

In the Lighten Up trial in Birmingham, England, 740 adults were assigned to one of 6 programs of 12 weeks, among them WeightWatchers, to a choice among those programs, or to a comparison group given 12 free visits to a leisure center; 100 were assigned to WeightWatchers. At 1 year, with 70.5 percent of all participants followed up and missing people counted as unchanged, only the WeightWatchers group had lost significantly more weight than the comparison group, 2.5 kilograms more, from 0.8 to 4.2. The trial was funded by the local National Health Service, not by the company (Jolly et al., 2011).

In the U.S. self-help trial, 423 adults at 6 academic centers were assigned to 2 brief sessions with a nutritionist plus self-help resources, or to the commercial program. At 2 years, 71 percent of the program group and 75 percent of the self-help group completed the study. In the intention-to-treat analysis, the program group lost 4.3 kilograms against 1.3 at 1 year, and 2.9 against 0.2 at 2 years, according to the abstract read for this page (Heshka et al., 2003). In the prediabetes trial, the program group lost 5.5 percent of body weight against 0.2 percent at 12 months (Marrero et al., 2016), and in the diabetes trial 4.0 percent against 1.9 percent (O'Neil et al., 2016).

Not every version made a clear difference at 12 months. A trial of Weight Watchers Online, the web-only version as the company offered it from 2013 to 2015, built on an earlier points system, assigned adults to the online program, the online program with an activity tracker, or an online newsletter. Its abstract reports 279 randomized; its full report's flow and baseline tables give 271, 94 to the online program, 91 to the program with the tracker and 86 to the newsletter, with 234 weighed at 12 months, and this page uses the full report's numbers.

Research staff who did not know the group assignments measured weights. At 3 months, the online program group had lost 2.7 kilograms against 1.3 with the newsletter. At 12 months the losses were 2.1 and 1.2 kilograms, and the trial could not tell whether the groups differed; that does not show they were the same (Thomas et al., 2017).

At 12 months, 24 of the 94 in the online program group had lost at least 5 percent of their weight, against 11 of the 86 in the newsletter group, and the group given an activity tracker did not lose more weight than the newsletter group. The company funded the trial and helped design it; the lead authors collected and analyzed the data independently. The abstract and the full report give different bounds for the P values of the 12-month comparison, and this page relies on the full report (Thomas et al., 2017).

For the current app-based program, the only randomized evidence found is a 6-month trial of 376 U.S. adults assigned to the program or to monthly emails drawing on the federal MyPlate website, described on the MyPlate page of this archive. The program group's weight changed by 5.4 percent against 1.5 percent, a difference of 3.9 percentage points, from 2.5 to 5.4. Participants weighed themselves at home on a scale the study provided and uploaded photos of the reading. Data were missing for 13.4 percent of the program group and 2.6 percent of the comparison group. The company funded the trial, and 3 authors were company employees who helped design it and write the report but, the report says, were not involved in collecting or analyzing data (Palacios et al., 2025).

A 2015 systematic review that did not pool results summarized 6 trials comparing the program with control or education and found that, at 12 months, the program produced "at least 2.6% greater weight loss" in intention-to-treat analyses; in 2 trials against behavioral counseling, results were mixed (Gudzune et al., 2015). The review's text describes the risk of bias of the 6 trials as moderate while its summary table lists it as high, and its table shows that 4 of the 6 received support from the company; this page reports both labels and relies on the individual trials it read. The correction notice describes adverse-event revisions and identifies no change to WeightWatchers weight estimates or risk-of-bias labels. The corrected supplement remains unchecked, and the text/table discrepancy is unresolved.

A 2020 network meta-analysis compared 14 named diets, Weight Watchers among them, with a usual diet, meaning participants told to keep their usual eating, combining direct comparisons with indirect ones through other diets, and rated its results with GRADE. At 6 months, it estimated 3.90 kilograms more weight loss with Weight Watchers than with a usual diet, 95 percent credible interval 2.52 to 5.31, at moderate certainty. For systolic blood pressure, it estimated 2.80 mm Hg lower, from 0.84 higher to 6.61 lower, at low certainty; for diastolic blood pressure, 1.03 mm Hg lower, from 0.70 higher to 2.79 lower, at low certainty; and for LDL cholesterol, 7.13 mg/dL lower, from 6.36 higher to 20.53 lower, at very low certainty. At 12 months, its weight estimate for the program was 2.98 kilograms, from 1.27 to 4.65, with no certainty rating in the tables read (Ge et al., 2020).

These ratings are carried exactly in the review record below, for their own comparison and time point, and are not transferred to the page's own rows. The review's authors published a correction in 2020 about how one trial was classified; they state that the changes are minor and do not affect the review's conclusions, and this page reads the figures from the copy in PubMed Central (Ge et al., 2020).

Mortality

The searches for this page did not identify a trial of the program that recorded deaths as an outcome. The trials were not designed or large enough to estimate any effect on survival, and the studies reviewed here do not establish one in either direction.

Eating behavior and wellbeing

In the English trial, quality of life changed little and did not differ between groups at 12 months (Ahern et al., 2017). At 5 years, 643 participants, 51 percent, attended the follow-up visit, and 474 were included in the analysis. No clear difference was found between the groups in changes in depression or anxiety symptoms on a standard questionnaire, and every interval for the difference fell within 2 points, the change the authors set as the smallest that matters. The authors note these are averages and that some individuals' symptoms rose or fell (Jones et al., 2022). That follow-up did not measure disordered eating.

In the 2025 trial of the app-based program, diet quality, scored on the Healthy Eating Index from 3 online 24-hour dietary recalls, rose by 5.3 points with the program and 1.1 points with emailed guidance, a difference of 4.2 points, from 1.8 to 6.6 (Palacios et al., 2025). Dietary recalls are self-reported, and members of a program that tracks food may report differently from people who do not.

Evidence from long-term prospective cohort studies

A cohort study follows people over time and records what happens to them. The searches for this page did not identify a cohort study that followed members and nonmembers for heart disease, diabetes, cancer or death. The observational studies found describe members only, so they can show who did well but not whether the program caused it.

Cardiometabolic outcomes

The searches did not identify a prospective cohort of members with cardiometabolic events as an outcome.

Cancer

The searches did not identify a prospective cohort of members with cancer as an outcome.

Body weight, as measured

Tennessee's Medicaid program offered memberships to its members in 2006. In a retrospective analysis of the 1,192 adults who had at least one follow-up weight, of 1,605 who started, the median weight loss was 1.9 kilograms, 1.8 percent of starting weight, and 20 percent lost at least 5 percent; the 23 percent who attended 13 or more meetings lost an average of 6.4 percent (Mitchell et al., 2013, read as an abstract). The company-funded survey of long-term maintainers described in section 2 is a cross-sectional comparison of people already selected for success (Phelan et al., 2020).

Mortality

The searches did not identify a cohort of members with death as an outcome.

The company's own data on the medical tier, examined

The largest numbers in the company's current advertising come from its medical tier. Its pages report that Med+ members prescribed a GLP-1 medicine lost about 21 percent of their body weight in 12 months, from internal analyses of about 3,250 members, and that members who used its GLP-1 behavior program at least 4 days a week lost 22.2 percent against 17.2 percent for those who never logged in. The footnotes say these are self-reported weights, not from randomized trials, and not independently verified (WW International, Inc., n.d.-a, n.d.-d).

Three limitations keep these figures from showing what the program adds. The members were taking prescription medicines, so the figures describe the medicine plus everything else and cannot separate the program's share. The comparison between frequent and infrequent app users compares people who chose how much to engage, and people who engage more may differ in many other ways. And the members counted are those who reported weights at 12 months, so people who stopped may be missing. The only randomized test of the program alongside a medicine found for this page was a 12-week trial of 101 patients of the company's telehealth clinic prescribed naltrexone and bupropion, in which those also given the behavioral program lost 1.8 kilograms more than those given the medicine alone; it was read as its abstract (Jones et al., 2026).

Highlighted studies

These 4 studies carry the most weight for this page: the 2 largest referral trials, the independently funded comparison of several programs, and the only trial of the current app-based program. Each is described so a reader can judge it without opening the paper.

On a narrow screen, scroll the table sideways to see every column.

Highlighted studies for WeightWatchers

Study	Design	Sample size	Duration	Finding	The limitation that matters
Jebb et al., 2011	Randomized controlled trial, 3 countries; free group meetings against standard care in primary care	772 adults randomized; 444 completed the 12-month assessment	12 months	2.77 kilograms more weight lost than standard care, from 2.03 to 3.50, counting missing people at their last weight; 2.29 kilograms counting them as unchanged	Only 58 percent completed; funded by the company, which delivered the program
Ahern et al., 2017 and 2022, the WRAP trial	Randomized controlled trial, England; 12 or 52 weeks of free meetings against brief advice	1,267 adults randomized; 65 percent measured at 1 year, 69 percent at 5 years	5 years of follow-up	2.71 kilograms more weight lost than brief advice at 1 year; 1.44 kilograms at 2 years, interval reaching no difference; at 5 years, 1.76 kilograms for 52 weeks, not statistically clear	Missing data; part-funded by the company through a research council award; the 5-year report was read as an abstract
Jolly et al., 2011, Lighten Up	Randomized controlled trial of 6 programs against free leisure-center visits	740 adults randomized, 100 to WeightWatchers	12 weeks of program, 1 year of follow-up	2.5 kilograms more weight lost than the comparison group at 1 year, from 0.8 to 4.2; the only program to differ from it at 1 year	Small arms of 100 people and 70.5 percent overall follow-up at 1 year
Palacios et al., 2025	Randomized controlled trial of the app-based program against emailed nutrition guidance	376 adults randomized; 330 with 6-month weights	6 months	Diet quality score 4.2 points higher, from 1.8 to 6.6; weight changed 3.9 percentage points more, from 2.5 to 5.4	Funded by the company with employee authors; weights taken at home; more missing data in the program group

Head to head

In a Boston trial, 160 adults with high blood pressure, high cholesterol or high fasting blood sugar were assigned to WeightWatchers, Atkins, Zone or Ornish diets, 40 to each. At 1 year, counting people who left as unchanged, the WeightWatchers group had lost an average of 3.0 kilograms, against 2.1 for Atkins, 3.2 for Zone and 3.3 for Ornish, and weight loss was associated with how closely people said they followed their diet rather than with which diet they followed; each diet lowered the ratio of LDL to HDL cholesterol by about 10 percent (Dansinger et al., 2005, read as an abstract). The Atkins, Zone and Ornish diets are separate entries on the archive index.

In the British diet trial, adults recruited through a BBC campaign were assigned to the Pure Points version, Atkins, Slim-Fast, Rosemary Conley's plan or a delayed-treatment control for 6 months; all 4 diets produced more weight and fat loss than the control, and the diet groups did not differ significantly from one another (Truby et al., 2006; the full report and its erratum were read for this archive). In Lighten Up, the 3 commercial programs together produced 2.3 kilograms more weight loss than the 3 primary care programs at the end of the 12 weeks (Jolly et al., 2011). In the trial of medicine with or without the program, described above, the comparison was the same medicine alone (Jones et al., 2026). These trials did not demonstrate that WeightWatchers produces more weight change than other structured diets.

Where the evidence is absent

The searches for this page, run on October 11, 2026 in Europe PMC and ClinicalTrials.gov, including a separate search for each special population this archive covers, did not identify a trial of the program that measured heart attacks, strokes, new diagnoses of diabetes, cancer or death, or a cohort study that followed members and nonmembers for those outcomes. The longest trial followed people for 5 years and found the weight difference no longer statistically clear. The current app-based program has been tested in one company-funded trial of 6 months, and the Med+ medical tier has no randomized comparison with usual care in the searches run.

The searches did not identify a trial in pregnancy, breastfeeding, children, older adults or athletes, or a study measuring the onset or return of disordered eating in members; several trials excluded people with eating disorders, under different definitions, and the English, 3-country, online and 2025 trials excluded pregnancy. They did not identify an independent study of what members spend or of the program's environmental footprint as members eat it. Registry searches found many trials associated with the company, several of them completed without results posted in the registry, so the published results may not be the whole picture. The studies reviewed here do not establish effects on these outcomes in either direction.

5. Mechanisms

(optional reading; select the heading to open or close this section)

This section explains how the program is thought to work. You can skip it. Nothing in the coaching sections depends on it.

Established mechanisms

The program is a structured way of eating less energy than the body uses. The Points Budget is set from a personal assessment, and the Points value of a food is calculated partly from its calories (WW International, Inc., 2026), so a budget of Points works in part as a limit on energy intake. The American Heart Association lists adjusting energy intake and expenditure to reach and keep a healthy body weight as the first feature of a heart-healthy dietary pattern (Lichtenstein et al., 2026). The trials measured the result of that energy deficit as weight change; in the British diet trial, all 4 commercial diets produced similar weight and fat loss over 6 months despite very different rules (Truby et al., 2006).

The program also packages behavior change techniques used in professionally delivered weight-loss treatment. The authors of the 3-country trial noted that the program uses self-monitoring, goal setting, nutrition advice and exercise advice, along with regular weighing and group support (Jebb et al., 2011). In several studies, people who attended more meetings or coaching sessions lost more weight (Cueto et al., 2019; Mitchell et al., 2013); those are associations within observational data and cannot show that attendance caused the difference.

Proposed mechanisms

The company proposes that its Points system steers members toward "more filling, nutrient-rich foods," by making protein and fiber lower the Points value of a food and leaving foods such as vegetables, fruit, beans and lean proteins untracked (WW International, Inc., n.d.-f, n.d.-g). The 2025 trial found higher diet quality scores with the program, which fits that idea, but it did not test whether the Points rules, rather than the coaching, the workshops or simply eating less, produced the change (Palacios et al., 2025).

The company also rests the program on the idea that "people trying to lose weight together succeed more often than those who go it alone" (WW International, Inc., 2026). The trials compared the whole program with less support, so they cannot say how much of the effect comes from the group itself. A proposed mechanism like these is a reason to study the program, not evidence that a particular part of it works.

6. Risks, contraindications and myths

(select the heading to open or close this section)

Warnings from professional or regulatory bodies

The sources opened for this page did not include a clinical safety warning about WeightWatchers from a professional or regulatory body, and this was not an exhaustive search of regulators, state attorneys general or courts. The one regulatory action identified concerns children's privacy: the 2022 Federal Trade Commission settlement over the Kurbo app, described in section 2, a privacy and commercial practice case and not a finding about the diet's effects on health (Federal Trade Commission, 2022).

The strongest clinical cautions in the sources opened come from the company itself. Its health notice states that it "isn't a medical organization and we can't give you medical advice," urges members to consult their primary health care provider before starting any plan that could result in weight loss, and says that "weight loss can create physical changes that should be medically monitored" and that "studies have shown, for example, that weight loss can aggravate gall bladder illness" (WW International, Inc., n.d.-c).

Nutrient gaps

Eating less food can mean taking in less of some nutrients. In the 8-week nutrient analysis from the British diet trial, people on the Pure Points version showed significant declines, measured against U.K. reference intakes, in riboflavin, niacin, potassium, calcium, magnesium, iron and zinc; the authors found "no evidence to suggest micronutrient deficiency" on any of the diets tested, and noted that groups with higher needs for nutrients such as folate, iron or calcium "may benefit from tailored dietary advice" (Truby et al., 2008). That analysis tested a version of the program from the early 2000s, used food diaries from people who completed it, and lasted 2 months.

Because no food is banned, what a member eats within the budget decides most of the nutrient picture. The searches for this page did not identify a study measuring nutrient status in members of the current program, or in members taking GLP-1 medicines, whose appetite the company says the medicines reduce (WW International, Inc., n.d.-d). Whether a particular member's choices meet their needs is a question for a registered dietitian.

Who should not follow it without medical supervision

The company itself excludes people under 18, people who are pregnant, and people with an active or recent diagnosis of anorexia nervosa or bulimia nervosa, and it does not allow members with a body mass index below 18.5 to set a weight-loss goal (WW International, Inc., n.d.-c, n.d.-i). It asks anyone being treated for a medical condition, taking prescription medication or following a therapeutic diet to show the plan to their health care provider and follow any changes the provider makes (WW International, Inc., n.d.-c).

From the sources on this page, add anyone taking insulin, a sulfonylurea or a meglitinide, because of the risk of low blood glucose when they eat less carbohydrate or skip meals (National Institute of Diabetes and Digestive and Kidney Diseases, n.d.); anyone with kidney disease, whose needs depend on its stage, laboratory results and whether they are on dialysis, or another condition managed with a prescribed diet; and anyone considering a weight-loss medicine, which only a prescriber can decide. The special populations list in section 3 is built from these cautions.

Medication interactions

A coach never adjusts medication. The point of knowing these is to know when the client should talk to the prescriber. Insulin, sulfonylureas and meglitinides can cause low blood glucose, and not eating enough carbohydrate or skipping or delaying meals makes it more likely (National Institute of Diabetes and Digestive and Kidney Diseases, n.d.).

In the diabetes trial, the participants' own physicians managed their medicines; about a quarter of the program group reduced their diabetes medicines over the year, and more of the program group reported symptoms of low blood sugar at 3 and 6 months (O'Neil et al., 2016). That is why the order matters: the client keeps the prescriber informed before a substantial change in eating, and the prescriber, not the coach, adjusts the medicine. Blood pressure medicines may also need review as weight and eating change. A client taking warfarin keeps the prescriber informed before a substantial change in eating, because the amount of vitamin K-containing food, such as leafy green vegetables, affects how the medicine works (National Library of Medicine, 2026).

On the medical tier, the company's affiliated clinicians prescribe weight-loss medicines, including GLP-1 medicines, and the company lists nausea, constipation and other gastrointestinal discomfort as their most common side effects (WW International, Inc., n.d.-d). A client on one of these medicines, whoever prescribed it, takes questions about dose, side effects and other medicines to the prescriber, and makes sure their own physician knows about it.

Signs it is going wrong

Physical signs that call for the client's care plan, a medical assessment or emergency help include shakiness, sweating or confusion in a client on insulin or a sulfonylurea, which may be low blood sugar and is treated first under the client's own plan, with emergency help if symptoms are severe or the person cannot manage the episode, before the prescriber is told; dizziness or fainting; vomiting that does not stop, inability to keep fluids down or severe abdominal pain in a client on a weight-loss medicine; unusual tiredness; and weight loss faster than the client's plan expects or that the client did not intend. Each is a reason to involve a clinician, not a diagnosis.

Eating behaviors need separate and careful reading, because many have ordinary explanations, such as a work schedule, food access, cultural practice or a household's routines. Skipping meals to save Points, eating very little before a weigh-in, distress after a day over budget, avoiding meals that cannot be tracked, or rejoining again and again with growing distress are worth asking about directly. The coach asks what the behavior is for, whether it causes distress, whether it narrows what the person eats, and whether it interferes with daily life. A real concern goes through the coach’s own referral process or the client's existing clinical plan, and the coach does not diagnose from a behavior alone.

Myths and where they came from

Myth: "It keeps the weight off for good."

Where it came from: the company's description of its purpose as helping people "keep it off" (WW International, Inc., n.d.-a), and real success stories. What is true: in the trials, the program groups lost more weight than comparison groups at 1 year, and all groups regained some weight afterward. In the longest trial, the difference from brief advice was smaller at 2 years and not statistically clear at 5 years (Ahern et al., 2017; Ahern et al., 2022). Some members do keep weight off for years, as a survey of selected long-term maintainers shows, but that survey cannot say how common it is (Phelan et al., 2020).

Myth: "It's the #1 doctor-recommended program, so it must work better than the others."

Where it came from: the company's advertising, footnoted to a 2023 survey of 500 doctors (WW International, Inc., n.d.-f). What is true: a survey of what doctors recommend measures popularity among those doctors, not outcomes. In the trials that compared the program directly with other popular diets, no clear difference in weight loss between the diets was found, and how closely people followed a diet mattered more than which diet it was (Dansinger et al., 2005; Truby et al., 2006).

Myth: "Med+ members lose 21 percent of their weight, so the program's habits are what work."

Where it came from: the company's advertising of its medical tier (WW International, Inc., n.d.-d). What is true: those figures come from members taking prescription medicines, as reported in the company's own data, which its footnotes describe as self-reported and not independently verified (WW International, Inc., n.d.-a). The one randomized trial found that adding the behavioral program to one medicine produced 1.8 kilograms more weight loss over 12 weeks than the medicine alone (Jones et al., 2026).

Myth: "If a food is zero points, it doesn't count."

Where it came from: the program's ZeroPoint list, foods the company says do not need to be weighed, measured or tracked (WW International, Inc., 2026). What is true: ZeroPoint foods still supply energy and nutrients; in the 2025 trial they were described as foods that promote a healthy dietary pattern, such as lean proteins, fruits, vegetables, beans and eggs (Palacios et al., 2025). Not tracking them is a program rule meant to make the plan simpler, not a finding that their amount does not matter.

7. Key terms

Points

The company's single number for a food, calculated by its own formula from the food's calories, saturated fat, unsaturated fat, added sugar, protein and fiber.

Points Budget

The daily and weekly number of Points the company assigns a member from a personal assessment.

ZeroPoint foods

More than 350 foods, such as many vegetables, fruits, beans and lean proteins, that the company says do not need to be weighed, measured or tracked.

Workshop

A coach-led group session, in person or online, included in the Core+ tier.

WeightWatchers Coach

A company role: a workshop leader the company trains in its own nutrition and behavior change approach. The company pages opened for this page do not list a professional health credential as a requirement, although an individual Coach may hold one; the role is distinct from a health and wellness coach working under a professional scope of practice.

Core, Core+ and Med+

The company's 3 membership tiers: the app; the app with workshops; and, in the United States, the app and workshops with access to affiliated clinicians who can prescribe weight-loss medicines.

GLP-1 medicine

A class of prescription medicines, given by injection or as a pill, that the company describes as helping people feel fuller and reducing appetite; prescribed only by a clinician.

Referral trial

A trial in which a family doctor or practice refers patients to a program, testing how it works when offered through routine health care.

Intention-to-treat analysis

An analysis that keeps every randomized person in the group they were assigned to, whether or not they followed the program, so that the comparison stays fair.

Last observation carried forward

A way of filling in a missing final weight by using the person's last recorded weight.

Baseline observation carried forward

A more cautious way of filling in a missing final weight by assuming the person did not change from the start.

HbA1c

A blood test that reflects average blood sugar over the previous few months.

Healthy Eating Index

A score that rates how closely a diet matches federal dietary guidance; the 2025 trial used it as its measure of diet quality.

Self-reported outcome

A result the person reports, such as a weight they enter in an app, rather than one measured by the study team.

GRADE

The 4-level scale used in clinical guidelines to say how certain the evidence for one outcome and one comparison is: high, moderate, low or very low.

Threshold

The smallest difference a study or review treats as large enough to matter, used on this page to judge whether a result is precise enough to rely on; for weight it is a way of reading a measurement, not a goal for a client.

8. Review questions

1. How does the Points system work, what is a ZeroPoint food, and how do the Core, Core+ and Med+ tiers differ?
2. Drawing on section 4: in the WRAP trial, what was compared, how many people were randomized and how many were measured, and how did the difference in weight change between 1 year and 5 years?
3. Drawing on section 4: which version of the program did the 3-country trial, the online trial and the 2025 trial each test, and why does that matter when a client asks whether the program works?
4. A client who takes insulin tells you she has just rejoined and plans to eat as little as her budget allows before her daughter's wedding. What does the coach do, and where are the referral lines?
5. Drawing on sections 4 and 6: the company says its Med+ members lose 21 percent of their body weight in 12 months. Where does that figure come from, and what would you need to know before treating it as evidence about the program?

9. References

Ahern, A. L., Breeze, P., Fusco, F., Sharp, S. J., Islam, N., Wheeler, G. M., Hill, A. J., Hughes, C. A., Duschinsky, R., Thomas, C., Bates, S., Woolston, J., Stubbings, M., Whittle, F., Boothby, C., Bostock, J., Jebb, S., Aveyard, P., Boyland, E., . . . Griffin, S. J. (2022). Effectiveness and cost-effectiveness of referral to a commercial open group behavioural weight management programme in adults with overweight and obesity: 5-year follow-up of the WRAP randomised controlled trial. The Lancet Public Health, 7(10), e866-e875. https://doi.org/10.1016/S2468-2667(22)00226-2

Ahern, A. L., Wheeler, G. M., Aveyard, P., Boyland, E. J., Halford, J. C. G., Mander, A. P., Woolston, J., Thomson, A. M., Tsiountsioura, M., Cole, D., Mead, B. R., Irvine, L., Turner, D., Suhrcke, M., Pimpin, L., Retat, L., Jaccard, A., Webber, L., Cohn, S. R., & Jebb, S. A. (2017). Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): A randomised controlled trial. The Lancet, 389(10085), 2214-2225. https://doi.org/10.1016/S0140-6736(17)30647-5

Apolzan, J. W., LaRose, J. G., Anton, S. D., Beyl, R. A., Greenway, F. L., Wickham, E. P., Lanoye, A., Harris, M. N., Martin, C. K., Bullard, T., Foster, G. D., & Cardel, M. I. (2023). A scalable, virtual weight management program tailored for adults with type 2 diabetes: Effects on glycemic control. Nutrition & Diabetes, 13, Article 3. https://doi.org/10.1038/s41387-023-00234-6

Cueto, V., Wang, C. J., & Sanders, L. M. (2019). Impact of a mobile app-based health coaching and behavior change program on participant engagement and weight status of overweight and obese children: Retrospective cohort study. JMIR mHealth and uHealth, 7(11), Article e14458. https://doi.org/10.2196/14458

Dansinger, M. L., Gleason, J. A., Griffith, J. L., Selker, H. P., & Schaefer, E. J. (2005). Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial. JAMA, 293(1), 43-53. https://doi.org/10.1001/jama.293.1.43

Federal Trade Commission. (2022, March 4). FTC takes action against company formerly known as Weight Watchers for illegally collecting kids' sensitive health data [Press release]. ftc.gov/news-events/news/press-releases/2022/03/ftc-takes-action-against-company-formerly-known-weight-watchers-illegally-collecting-kids-sensitive

Ge, L., Sadeghirad, B., Ball, G. D. C., da Costa, B. R., Hitchcock, C. L., Svendrovski, A., Kiflen, R., Quadri, K., Kwon, H. Y., Karamouzian, M., Adams-Webber, T., Ahmed, W., Damanhoury, S., Zeraatkar, D., Nikolakopoulou, A., Tsuyuki, R. T., Tian, J., Yang, K., Guyatt, G. H., & Johnston, B. C. (2020). Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: Systematic review and network meta-analysis of randomised trials. BMJ, 369, Article m696. https://doi.org/10.1136/bmj.m696

Gudzune, K. A., Doshi, R. S., Mehta, A. K., Chaudhry, Z. W., Jacobs, D. K., Vakil, R. M., Lee, C. J., Bleich, S. N., & Clark, J. M. (2015). Efficacy of commercial weight-loss programs: An updated systematic review. Annals of Internal Medicine, 162(7), 501-512. https://doi.org/10.7326/M14-2238

Heshka, S., Anderson, J. W., Atkinson, R. L., Greenway, F. L., Hill, J. O., Phinney, S. D., Kolotkin, R. L., Miller-Kovach, K., & Pi-Sunyer, F. X. (2003). Weight loss with self-help compared with a structured commercial program: A randomized trial. JAMA, 289(14), 1792-1798. https://doi.org/10.1001/jama.289.14.1792

Jebb, S. A., Ahern, A. L., Olson, A. D., Aston, L. M., Holzapfel, C., Stoll, J., Amann-Gassner, U., Simpson, A. E., Fuller, N. R., Pearson, S., Lau, N. S., Mander, A. P., Hauner, H., & Caterson, I. D. (2011). Primary care referral to a commercial provider for weight loss treatment versus standard care: A randomised controlled trial. The Lancet, 378(9801), 1485-1492. https://doi.org/10.1016/S0140-6736(11)61344-5

Jelalian, E., Darling, K., Foster, G. D., Runyan, T., & Cardel, M. I. (2023). Effectiveness of a scalable mHealth intervention for children with overweight and obesity. Childhood Obesity, 19(8), 552-559. https://doi.org/10.1089/chi.2022.0154

Jolly, K., Lewis, A., Beach, J., Denley, J., Adab, P., Deeks, J. J., Daley, A., & Aveyard, P. (2011). Comparison of range of commercial or primary care led weight reduction programmes with minimal intervention control for weight loss in obesity: Lighten Up randomised controlled trial. BMJ, 343, Article d6500. https://doi.org/10.1136/bmj.d6500

Jones, R. A., Lee, A. M., Foster, G. D., Nadolsky, S., Killion, K., Gentry, L. N., Zeldman, J., Hong, Y.-R., Medcalf, A., Estes, F., Richardson, K. M., & Cardel, M. I. (2026). Efficacy of oral antiobesity medications with versus without adjunct behavioral weight management treatment. Obesity, 34(3), 588-597. https://doi.org/10.1002/oby.70127

Jones, R. A., Mueller, J., Sharp, S. J., Griffin, S. J., & Ahern, A. L. (2022). Long-term impact of a behavioral weight management program on depression and anxiety symptoms: 5-year follow-up of the WRAP trial. Obesity, 30(12), 2396-2403. https://doi.org/10.1002/oby.23570

Lichtenstein, A. H., Khera, A., Anderson, C. A. M., Appel, L. J., DeSilva, D. M., Gardner, C., Hu, F. B., Jones, D. W., Petersen, K. S., & American Heart Association. (2026). 2026 dietary guidance to improve cardiovascular health: A scientific statement from the American Heart Association. Circulation, 153(18), e1285-e1295. https://doi.org/10.1161/CIR.0000000000001435

Marrero, D. G., Palmer, K. N. B., Phillips, E. O., Miller-Kovach, K., Foster, G. D., & Saha, C. K. (2016). Comparison of commercial and self-initiated weight loss programs in people with prediabetes: A randomized control trial. American Journal of Public Health, 106(5), 949-956. https://doi.org/10.2105/AJPH.2015.303035

Mehta, A. K., Doshi, R. S., Chaudhry, Z. W., Jacobs, D. K., Vakil, R. M., Lee, C. J., Bleich, S. N., Clark, J. M., & Gudzune, K. A. (2016). Benefits of commercial weight-loss programs on blood pressure and lipids: A systematic review. Preventive Medicine, 90, 86-99. https://doi.org/10.1016/j.ypmed.2016.06.028

Mitchell, N. S., Ellison, M. C., Hill, J. O., & Tsai, A. G. (2013). Evaluation of the effectiveness of making Weight Watchers available to Tennessee Medicaid (TennCare) recipients. Journal of General Internal Medicine, 28(1), 12-17. https://doi.org/10.1007/s11606-012-2083-8

National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Low blood glucose (hypoglycemia). niddk.nih.gov/health-information/diabetes/overview/preventing-problems/low-blood-glucose-hypoglycemia

National Library of Medicine. (2026, March 15). Warfarin. MedlinePlus. medlineplus.gov/druginfo/meds/a682277.html

Neff, R. A., Ramsing, R. J., & Kim, B. F. (2023). Commercial weight-loss diets, greenhouse gas emissions and freshwater consumption. Journal of Human Nutrition and Dietetics, 36(6), 2268-2279. https://doi.org/10.1111/jhn.13248

O'Neil, P. M., Miller-Kovach, K., Tuerk, P. W., Becker, L. E., Wadden, T. A., Fujioka, K., Hollander, P. L., Kushner, R. F., Garvey, W. T., Rubino, D. M., Malcolm, R. J., Weiss, D., Raum, W. J., Salyer, J. L., Hermayer, K. L., Rost, S. L., Veliko, J. L., & Sora, N. D. (2016). Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes. Obesity, 24(11), 2269-2277. https://doi.org/10.1002/oby.21616

Palacios, A. M., Lee, A. M., Parker, C., Watts, C. Q., Dickinson, S. L., Henschel, B., Anderson, G., Kersey, J. X., Allison, D. B., Foster, G. D., & Cardel, M. I. (2025). Effectiveness of a digital weight management program on diet quality: A randomized controlled trial. The American Journal of Clinical Nutrition, 122(3), 830-840. https://doi.org/10.1016/j.ajcnut.2025.06.024

Phelan, S., Halfman, T., Pinto, A. M., & Foster, G. D. (2020). Behavioral and psychological strategies of long-term weight loss maintainers in a widely available weight management program. Obesity, 28(2), 421-428. https://doi.org/10.1002/oby.22685

Semnani-Azad, Z., Khan, T. A., Chiavaroli, L., Chen, V., Bhatt, H. A., Chen, A., Chiang, N., Oguntala, J., Kabisch, S., Lau, D. C., Wharton, S., Sharma, A. M., Harris, L., Leiter, L. A., Hill, J. O., Hu, F. B., Lean, M. E., Kahleová, H., Rahelic, D., . . . Sievenpiper, J. L. (2025). Intermittent fasting strategies and their effects on body weight and other cardiometabolic risk factors: Systematic review and network meta-analysis of randomised clinical trials. BMJ, 389, Article e082007. https://doi.org/10.1136/bmj-2024-082007

Thomas, J. G., Raynor, H. A., Bond, D. S., Luke, A. K., Cardoso, C. C., Foster, G. D., & Wing, R. R. (2017). Weight loss in Weight Watchers Online with and without an activity tracking device compared to control: A randomized trial. Obesity, 25(6), 1014-1021. https://doi.org/10.1002/oby.21846

Tocque, K., & Kennedy, L. (2022). Can Weight Watchers (WW) help address maternal obesity? An audit of weight change in women of childbearing age and mothers-to-be, referred into a commercial slimming programme. Maternal and Child Health Journal, 26(5), 1038-1048. https://doi.org/10.1007/s10995-021-03204-5

Truby, H., Baic, S., deLooy, A., Fox, K. R., Livingstone, M. B. E., Logan, C. M., Macdonald, I. A., Morgan, L. M., Taylor, M. A., & Millward, D. J. (2006). Randomised controlled trial of four commercial weight loss programmes in the UK: Initial findings from the BBC "diet trials." BMJ, 332(7553), 1309-1314. https://doi.org/10.1136/bmj.38833.411204.80

Truby, H., Hiscutt, R., Herriot, A. M., Stanley, M., deLooy, A., Fox, K. R., Baic, S., Robson, P. J., Macdonald, I., Taylor, M. A., Ware, R., Logan, C., & Livingstone, M. B. E. (2008). Commercial weight loss diets meet nutrient requirements in free living adults over 8 weeks: A randomised controlled weight loss trial. Nutrition Journal, 7, Article 25. https://doi.org/10.1186/1475-2891-7-25

U.S. Securities and Exchange Commission. (n.d.). EDGAR submissions record for WW International, Inc., CIK 0000105319. data.sec.gov/submissions/CIK0000105319.json

WW International, Inc. (n.d.-a). About WW International. weightwatchers.com/us/about-ww

WW International, Inc. (n.d.-b). Core+. weightwatchers.com/us/core-plus

WW International, Inc. (n.d.-c). Health notices. weightwatchers.com/us/termsandconditions/health-notice

WW International, Inc. (n.d.-d). Online prescription weight-loss medication. weightwatchers.com/us/weight-loss-medication

WW International, Inc. (n.d.-e). Registered dietitians. weightwatchers.com/us/registered-dietitians

WW International, Inc. (n.d.-f). Weight loss program, recipes and help. weightwatchers.com/us/plans

WW International, Inc. (n.d.-g). Weight Watchers Points Program: Trusted and science-backed. weightwatchers.com/us/how-it-works/points-program

WW International, Inc. (n.d.-h). WW Clinic membership agreement. weightwatchers.com/us/termsandconditions/ww-clinic

WW International, Inc. (n.d.-i). WW membership agreement. weightwatchers.com/us/termsandconditions/membership

WW International, Inc. (2020, December 31). Kurbo by WW (Weight Watchers): Weight loss for teens and kids. Internet Archive capture. web.archive.org/web/20201231092706/https://kurbo.com/

WW International, Inc. (2026). Annual report on Form 10-K for the fiscal year ended December 31, 2025. U.S. Securities and Exchange Commission. sec.gov/Archives/edgar/data/105319/000119312526107176/ww-20251231.htm

Evidence rating and review record

Each row identifies the method, source, outcome or recommendation, and comparison being rated. Ratings from different tools are not interchangeable. The source is either a named published review or this page's own judgment. The rating in the banner is for this diet's main claimed outcome or recommendation, and the banner names the tool that produced it. A high rating means the research is solid; it does not mean the diet is right for everyone, and it does not mean a coach should recommend it.

The rated outcomes on this page use GRADE, which uses the same 4-level scale as the clinical guidelines you will meet in practice. High means further research is very unlikely to change the conclusion. Moderate means further research may change it. Low means further research is likely to change it. Very low means the conclusion is uncertain. GRADE rates each outcome separately, so a diet can be high for one outcome and very low for another. A row marked Not rated is an abstention, not a certainty level.

Four rows carry, exactly as published, the GRADE ratings of a 2020 network meta-analysis for outcomes at 6 months against a usual diet (Ge et al., 2020), the only published GRADE rating of the program the searches for this page identified. Every other row is this page's own judgment; the 2015 and 2016 reviews described in section 4 judged risk of bias but did not assign certainty ratings.

Four things about this table matter before reading it. The rows say which version of the program was tested, and a rating for one version does not transfer to another. Weight is rated as a measured outcome, never as a goal. Rows resting on an abstract alone are marked provisional, because the full report was not read. And each of this page's own rows names the threshold it used to judge whether a difference is large enough to matter; a threshold is a way of reading a measurement, not a goal for a client.

On a narrow screen, scroll the table sideways to see every column.

Evidence ratings, their sources and reasons

Outcome	Certainty	Who rated it, and for which comparison	Why it is rated this way
Measured body weight at about 12 months, adults with overweight or obesity (the banner rating)	Moderate	GRADE, this page's own judgment. Group-meeting versions of the program, tested from 1998 to 2014: 12 months of meetings against standard care (Jebb et al., 2011); 12 or 52 weeks against brief advice (Ahern et al., 2017); 12 weeks against free leisure-center visits (Jolly et al., 2011); and the program against self-help (Heshka et al., 2003, read as an abstract). The prediabetes and type 2 diabetes trials are described in section 4 and not counted here	Randomized trials start high. Thresholds: 1 kilogram for judging precision and 2 kilograms for judging whether a difference matters, the thresholds a 2025 review of weight-loss diets used (Semnani-Azad et al., 2025); they are ways of reading a measurement, not goals. Lowered 1 level for risk of bias: 29.5 to 42 percent of 12-month weights were missing in the 3 trials with intervals, so results depend on how missing weights were filled in; in the 3-country trial the difference was 2.77 kilograms counting missing people at their last weight and 2.29 counting them as unchanged. Staff weighed participants on scales, which limits bias from participants knowing their group, and where reported the company had no role in the analysis. Not lowered for inconsistency: estimates of 2.29 to 3.0 kilograms with overlapping intervals. Not lowered for indirectness for these versions; the row does not transfer to the app or Med+. Not lowered for imprecision: the 2 largest trials, which carry most of the weight of the evidence, have intervals entirely above 1 kilogram, 2.03 to 3.50 and 1.55 to 3.86; the smallest, Lighten Up, crosses it, 0.8 to 4.2. Publication bias is possible, given company-associated registry entries without posted results, but no level was taken, because the independently funded Lighten Up trial agrees. Nothing raises the rating.
Measured body weight at 6 months, the app-based program sold in 2023, with virtual workshops	Moderate	GRADE, this page's own judgment. Palacios et al., 2025: the program against monthly emailed nutrition guidance, 376 U.S. adults	Randomized trial starts high. Thresholds as in the first row. Lowered 1 level for risk of bias: participants weighed themselves at home, with a photo of the scale; missing data were much higher in the program group, 13.4 against 2.6 percent, although sensitivity analyses gave consistent results; and the company funded the trial and employed authors who helped design it, though not, the report says, collect or analyze the data. Allocation was concealed and the investigators were blinded. Inconsistency cannot be assessed from one trial, which is not a reason to lower. Not lowered for indirectness for this version over 6 months; it does not transfer to longer use or later versions. Not lowered for imprecision: the difference, 3.9 kilograms, has an interval of 2.5 to 5.3 kilograms, entirely above both thresholds. Publication bias was not detected. Nothing raises the rating.
Weight loss at 6 months, against a usual diet, network estimate	Moderate	GRADE, published: Ge et al., 2020, a network meta-analysis of 14 named diets combining direct and indirect comparisons; Weight Watchers against a usual diet, meaning participants told to keep their usual eating	Carried exactly as published. Estimate 3.90 kilograms more weight loss, 95 percent credible interval 2.52 to 5.31. At 12 months the review estimated 2.98 kilograms, 1.27 to 4.65, and the tables read for this page give no certainty rating for it. Not transferred to any other comparison or time point.
Measured body weight at 2 years, group-meeting versions	Low	GRADE, this page's own judgment. Ahern et al., 2017: the 12-week and 52-week program groups together against brief advice at 24 months; and Heshka et al., 2003, read as an abstract: the program against self-help at 2 years	Randomized trials start high. Thresholds as in the first row. Lowered 1 level for risk of bias: about a third of WRAP participants were missing at 24 months, and how Heshka handled missing data cannot be judged from its abstract. Lowered 1 level for imprecision: WRAP's difference, 1.44 kilograms, has an interval from 0.00 to 2.87 kilograms, which includes no difference and differences above 2 kilograms; Heshka's abstract gives no interval. Not lowered for inconsistency: both trials favor the program, by 1.44 and about 2.7 kilograms. Not lowered for indirectness, although the comparisons differ: brief advice in one, 2 sessions with a nutritionist plus self-help in the other. Publication bias not lowered. Nothing raises the rating. A full reading of Heshka is still needed.
Measured body weight at 5 years, 52-week program against brief advice	Low, provisional	GRADE, this page's own judgment. Ahern et al., 2022, read as an abstract: 871 of 1,267 measured	Randomized trial starts high. Thresholds as in the first row. Lowered 1 level for risk of bias: 31 percent of weights were missing, and the abstract does not show how missing data were handled. Lowered 1 level for imprecision: the difference, 1.76 kilograms, has an interval from 3.68 kilograms more to 0.17 kilograms less, which includes no difference and differences above 2 kilograms. Inconsistency cannot be assessed from one trial. Not lowered for indirectness. Publication bias not lowered. Low certainty does not show the program has no long-term effect. Provisional, because the full report and its published correction were not read, and this page does not assume the correction leaves these numbers unchanged.
Measured body weight at 5 years, 12-week program against brief advice	Low, provisional	GRADE, this page's own judgment. Ahern et al., 2022, read as an abstract: 871 of 1,267 measured	Randomized trial starts high. Thresholds as in the first row. Lowered 1 level for risk of bias, as in the row above. Lowered 1 level for imprecision: the difference, 0.96 kilograms, has an interval from 2.90 kilograms more to 0.97 kilograms less, which includes differences above 2 kilograms in favor of the program and nearly 1 kilogram against it; not lowered a second level, because the interval does not reach 1 kilogram against the program. Inconsistency cannot be assessed from one trial. Not lowered for indirectness. Publication bias not lowered. Provisional for the same reasons as the row above.
HbA1c at 12 months, adults with type 2 diabetes	Moderate	GRADE, this page's own judgment. O'Neil et al., 2016, read in full: the standard program plus telephone and email support from a certified diabetes educator, against one session of diabetes nutrition counseling with written materials, 563 adults at 16 U.S. centers	Randomized trial starts high. Threshold: 0.3 percentage points, the difference the trial was planned to detect. Not lowered for risk of bias: allocation was concealed, blood was analyzed by a central laboratory blind to group, and the data were analyzed independently of the company that funded the trial; HbA1c was missing for 20 percent of the program group and 12 percent of the standard care group, but analyses that handled missing data in 2 other ways gave nearly identical results. Participants knew their group, and their own physicians changed diabetes medicines during follow-up, with reductions more common in the program group. The result therefore describes this program-plus-educator package alongside ordinary physician-managed diabetes care; it does not isolate the eating plan's effect from medication management. Inconsistency cannot be assessed from one trial. Not lowered for indirectness for this package; it does not transfer to the program without the diabetes educator or to the current app. Lowered 1 level for imprecision: the difference, about 0.48 points, has an approximate interval of 0.25 to 0.71, calculated for this page from the 2 groups' intervals because the paper reports none for the difference, and its lower end falls below 0.3. Publication bias not lowered. Nothing raises the rating.
Systolic blood pressure at 12 months, group-meeting versions	Moderate, for little or no difference	GRADE, this page's own judgment. Ahern et al., 2017: 52-week and 12-week programs, each against brief advice; Jebb et al., 2011: 12 months of meetings against standard care; adults with overweight or obesity, most with blood pressure in the normal range at the start	Randomized trials start high. Threshold: 3 mm Hg, the smallest difference a 2020 review of named diets treated as important (Ge et al., 2020). Lowered 1 level for risk of bias: a third or more of 12-month measurements were missing, and the staff who measured blood pressure knew the groups. Not lowered for inconsistency: both trials found small differences, 0.59 to 1.04 mm Hg lower with the program. Not lowered for indirectness for adults like those enrolled; people with high blood pressure may respond differently. Not lowered for imprecision: WRAP's intervals reach just past 3 mm Hg lower, to 3.64 and 3.18, but a combined estimate from the 2 trials, calculated for this page, is about 0.8 mm Hg lower, from 2.2 lower to 0.6 higher, within the threshold. Publication bias not lowered. Nothing raises the rating. A small benefit is not ruled out.
Diastolic blood pressure at 12 months, group-meeting versions	Moderate, for little or no difference	GRADE, this page's own judgment. The same 2 trials and comparisons as the row above	Randomized trials start high. Threshold: 2 mm Hg, the smallest difference the same 2020 review treated as important (Ge et al., 2020). Lowered 1 level for risk of bias, as in the row above. Not lowered for inconsistency: 0.64 to 1.20 mm Hg lower with the program. Not lowered for indirectness, with the same caution about people with high blood pressure. Not lowered for imprecision: WRAP's intervals reach past 2 mm Hg lower, to 2.98 and 2.52, but a combined estimate from the 2 trials, calculated for this page, is about 0.8 mm Hg lower, from 1.7 lower to 0.1 higher, within the threshold. Publication bias not lowered. Nothing raises the rating.
LDL cholesterol at 12 months, group-meeting versions	Low, for uncertainty about an important difference	GRADE, this page's own judgment. The same 2 trials and comparisons as the rows above; blood results for 830 of 1,267 in WRAP	Randomized trials start high. Threshold: 5 mg/dL, about 0.13 mmol/L, the smallest difference the 2020 review of named diets treated as important (Ge et al., 2020). Lowered 1 level for risk of bias: blood samples were missing for about a third of WRAP participants, and missing values in the 3-country trial were filled in by assumption. Not lowered for inconsistency: the principal estimates were 0.00 to 0.05 mmol/L lower. Not lowered for indirectness for the versions and adults studied. Lowered 1 level for imprecision: the page's approximate combination of Jebb's last-observation analysis and WRAP's 52-week arm is 0.04 mmol/L lower, with an interval from 0.12 lower to 0.03 higher, inside the threshold. However, using Jebb's baseline-observation sensitivity analysis instead gives about 0.08 mmol/L lower, from 0.14 to 0.02 lower, crossing the threshold for an important reduction. These calculations use the reported rounded intervals and count the WRAP comparison group once. The conclusion about an important difference is sensitive to the missing-data analysis, so little or no important difference is not established. Publication bias not lowered. Nothing raises the rating. High minus 2 levels is Low.
Systolic blood pressure at 6 months, against a usual diet, network estimate	Low	GRADE, published: Ge et al., 2020; Weight Watchers against a usual diet	Carried exactly as published. Estimate 2.80 mm Hg lower, 95 percent credible interval from 0.84 higher to 6.61 lower. Not transferred to any other comparison or time point.
Diastolic blood pressure at 6 months, against a usual diet, network estimate	Low	GRADE, published: Ge et al., 2020; Weight Watchers against a usual diet	Carried exactly as published. Estimate 1.03 mm Hg lower, 95 percent credible interval from 0.70 higher to 2.79 lower. Not transferred to any other comparison or time point.
LDL cholesterol at 6 months, against a usual diet, network estimate	Very low	GRADE, published: Ge et al., 2020; Weight Watchers against a usual diet	Carried exactly as published. Estimate 7.13 mg/dL lower, 95 percent credible interval from 6.36 higher to 20.53 lower. Not transferred to any other comparison or time point.
Diet quality, Healthy Eating Index score at 6 months	Low	GRADE, this page's own judgment. Palacios et al., 2025: the app-based program against monthly emailed nutrition guidance	Randomized trial starts high. Threshold: 5 points, which the trial's authors cite as one study's estimate of a clinically relevant change, while noting that no threshold is settled (Palacios et al., 2025). Lowered 1 level for risk of bias: diet was self-reported in online recalls by participants who knew their group, and missing data were higher in the program group. Inconsistency cannot be assessed from one trial. Not lowered for indirectness; a diet quality score is a measure of eating, not a health outcome. Lowered 1 level for imprecision: the difference, 4.2 points, has an interval of 1.8 to 6.6, which includes differences below and above 5 points. Publication bias not lowered. Nothing raises the rating.
Depression symptoms at 5 years	Low, for little or no difference	GRADE, this page's own judgment. Jones et al., 2022: the WRAP trial's 52-week and 12-week program groups, each against brief advice, on the Hospital Anxiety and Depression Scale; 643 of 1,267 attended the 5-year visit and 474 were analyzed	Randomized trial starts high. Threshold: 2 points, the change the authors set as the smallest that matters. Lowered 2 levels for very serious risk of bias: 49 percent did not attend the 5-year visit, only 66 of the brief-advice group were analyzed, and the planned multiple imputation was not used because missing data passed the level the authors had set for it; those who attended may differ from those who did not. Inconsistency cannot be assessed from one trial. Not lowered for indirectness. Not lowered for imprecision: the differences, 0.06 points lower with 52 weeks and 0.07 higher with 12 weeks, have intervals within 0.9 points either way, inside the threshold. Publication bias not lowered. Nothing raises the rating. These are averages; some individuals' symptoms rose or fell.
Anxiety symptoms at 5 years	Low, for little or no difference	GRADE, this page's own judgment. The same trial, comparisons and analysis as the row above	Randomized trial starts high. Threshold: 2 points, as in the row above. Lowered 2 levels for very serious risk of bias, as in the row above. Inconsistency cannot be assessed from one trial. Not lowered for indirectness. Not lowered for imprecision: the difference with 52 weeks, 0.59 points lower, has an interval from 1.51 lower to 0.33 higher, and the difference with 12 weeks is close to 0 with an interval within 1 point either way, both inside the threshold. Publication bias not lowered. Nothing raises the rating.
Weight change reported by Med+ members prescribed a GLP-1 medicine	Very low	GRADE, this page's own judgment. The company's internal analyses of about 3,250 to 3,325 members (WW International, Inc., n.d.-a, n.d.-d). Comparison: none for the program; frequent against infrequent app users	Observational data start low. Risk of bias, very serious: weights are self-reported and not independently verified, members are counted only if they reported a weight at 12 months, and engagement was chosen by members, not assigned. Indirectness, serious for the program: members were taking a prescribed medicine, so the data cannot separate the program's share, nor show how much came from the medicine. Inconsistency and imprecision cannot be assessed: no intervals are reported, and the member counts differ. Publication bias: selective reporting is suspected, because the figures appear in marketing summaries. Nothing raises the rating. Very low is the lowest level, and it does not show that the program adds nothing.
Heart attacks, strokes, cancer and death	Not rated	This page's own judgment. The program against any comparison	The Europe PMC and ClinicalTrials.gov searches for this page did not identify a trial or cohort study of the program that measured these outcomes. This is an absence of evidence in those searches, not a finding of no effect or of safety.
Onset or return of disordered eating	Not rated	This page's own judgment. Members against nonmembers, including people with and without a history of disordered eating	The searches for this page did not identify a study measuring this outcome in members. Several trials excluded people with eating disorders, under different definitions, and the online trial kept people with binge eating disorder eligible. The company's exclusion of people with active or recent anorexia nervosa or bulimia nervosa is a company safety rule, not a research finding (WW International, Inc., n.d.-c). The low blood sugar reports in the diabetes trial and the Kurbo privacy settlement concern other questions and are not evidence on this outcome.

How this archive talks about weight. This page reports what studies measured, including body weight, and does not treat weight change as a goal or as a measure of a diet's success. Weight a person loses without meaning to can be a sign of a health problem, and where it is, the page names it as a reason to see a clinician. People are described the way the study described them.

Last reviewed: Reviewed and approved by James Peth, MS, MPH, PhD, on October 11, 2026, after a combined final review of the fourth batch of 5 archive pages, the commercial programs, the repairs it asked for and a targeted recheck. Written October 11, 2026. The judgments in the table, apart from the 4 rows carried from a published review, are this page's own, assigned from the evidence. Some sources could be read only as abstracts or author manuscripts, and the page says so where each is used. Company prices and terms are a snapshot from the company's own pages on October 11, 2026, and can change.

Updated October 21, 2026: The 2015 review's correction notice and the British diet trial's full report and erratum were read for this archive, and the 2 sentences that described them as unread were narrowed. No rating changed.

Next scheduled review: Each year, because the company changes its prices, tiers and program often and emerged from bankruptcy in 2025. Pages built on annual guidance are rechecked each year.

---

Diet Reference Archive | One James

Prepared by James Peth, MS, MPH, PhD

© 2026–2027 One James. All rights reserved.

This page is for education and coaching practice. It is not medical or dietary advice.